Recursion Pharmaceuticals Inc (RXRX) Stock AnalysisRXRXRecursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Recursion Pharmaceuticals Inc (RXRX) is a good buy right now, especially considering the recent surge in milestone payments from its collaboration with Sanofi, which could exceed $300 million. The current price of $3.465 is significantly below the analyst price target of $5.50, indicating a potential upside of 58.6%. Additionally, the RSI is at 35.676, suggesting that the stock is oversold and may be due for a rebound. However, the main risk is the recent 20.53% decline over the last five days, indicating volatility.